OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition
Prof. John Kastelein, AMC, Amsterdam, The Netherlands comments on the results of the OSLER program with PCSK9 inhibitor evolocumab and provides a perspective on the therapeutic potential of PCSK9 inhibitors. Prof Kastelein is looking forward to the large scale clinical outcome trial FOURIER to confirm the results.
News • 16-3-2015
3 minute education • 15-3-2015, ACC 2015, San Diego, Marc Sabatine, MD Boston
News • 17-3-2015
Literature • 19-3-2015 • Robinson et al., NEJM 2015
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.